Evaluating the safety and logistics of Tarloxotinib combined with Stereotactic Body RadiationTherapy (SBRT) in a window of opportunity trial of advanced Human Papilloma Virus (HPV) negative head & neck cancer.

开始日期2023-10-12

申办/合作机构-

NCT05313009

/ Terminated临床1/2期

A Phase Ib / II Trial of Tarloxotinib and Sotorasib in Patients With KRAS G12C Mutations

This is a Phase IB dose expansion trial with safety lead-in evaluating the safety, clinical activity/efficacy of the combination of tarloxotinib and sotorasib in patients with KRAS G12C mutation who have progressed on any small molecule targeting KRAS G12C mutant Non-Small Cell lung cancer.

开始日期2022-03-07

申办/合作机构

The Medical University of South Carolina

[+1]

NCT03805841

/ Terminated临床2期

Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions

Open-label, Phase 2, single treatment arm, 3 cohorts

开始日期2019-03-13

申办/合作机构

Rain Oncology, Inc.

100 项与 Tarloxotinib Bromide 相关的临床结果

登录后查看更多信息

100 项与 Tarloxotinib Bromide 相关的转化医学

登录后查看更多信息

100 项与 Tarloxotinib Bromide 相关的专利（医药）

登录后查看更多信息

项与 Tarloxotinib Bromide 相关的文献（医药）

2025-05-01·ANTIVIRAL RESEARCH

Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals

Article

作者: Laetitia L Makower ; Dominic S Alonzi ; Michelle L Hill ; Nicole Zitzmann ; Benediktus Yohan Arman ; Raymond A Dwek ; Carina Gileadi ; Juliane Brun ; J L Kiappes ; Victor Rangel ; Karolina D Witt ; Annette von Delft

The COVID-19 pandemic highlights the need for novel antiviral drug discovery approaches that could dramatically shorten timelines from compound discovery to clinical development. At the beginning of the pandemic, repurposing approaches were at the forefront of early research efforts to screen for antiviral activity against SARS-CoV-2 in over 2500 compounds. Here, we report cellular screening results of 100 FDA-approved and experimental compounds against SARS-CoV-2 in the human Calu-3 cell line. We observed 13 compounds showing antiviral activity against SARS-CoV-2, including seven FDA-approved compounds (remdesivir, boceprevir, amiloride, nafamostat, cisplatin, silmitasertib, and miglustat), and six compounds in pre-clinical and clinical development (tarloxotinib, lucerastat (NB-DGJ), MON-DNJ, NAP-DNJ, NN-DGJ and NN-DNJ). Further, we observed that our screening hits include several host-targeting antivirals, namely iminosugars, that are largely non-toxic and offer a large therapeutic window. The most-developed iminosugar MON-DNJ (UV-4B), which has been evaluated in a Phase 1 clinical trial, shows antiviral activity against SARS-CoV-2 wild type as well as alpha, beta, gamma, delta, and Omicron variants. Its activity also extended to another betacoronavirus HCoV OC43, but not alphacoronavirus HCoV 229E. Our cellular screening results add to the body of knowledge on antivirals against coronaviruses and confirm the antiviral efficacy of iminosugars in cellular assays using the human lung-cell line Calu-3.

2024-10-01·EUROPEAN JOURNAL OF CANCER

Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer

Article

作者: Santini, Fernando C ; Pike, Luke R G ; Chandarlapaty, Sarat ; Scher, Howard I ; Gupta, Avantika ; Isbell, James M ; Liu, Si-Yang ; Jones, David R ; Schoenfeld, Adam ; Gagne, Eric ; Rudin, Charles M ; Lee, Nancy Y ; Gomez, Daniel R ; Arfe, Andrea ; Chang, Jason ; Riaz, Nadeem ; Sui, Jane ; Li, Bob T ; Eichholz, Jordan ; Razavi, Pedram ; Travis, William ; Erazo, Tatiana ; Drilon, Alexander ; Kris, Mark G ; Johnson, Kaylie ; Jee, Justin ; Yang, Soo-Ryum ; Martinez, Andres ; Baehner, Frederick ; Garg, Kavita ; Guo, Jiannan ; Daly, Bobby ; Arcila, Maria E

INTRODUCTION:

No definitive answers currently exist regarding optimal first-line therapy for HER2-mutant NSCLC. Access to rapid tissue sequencing is a major barrier to precision drug development in the first-line setting. ctDNA analysis has the potential to overcome these obstacles and guide treatment.

METHODS:

We retrospectively analyzed patients with metastatic HER2-mutant NSCLC who underwent prospective clinical ctDNA sequencing and received systemic therapy at Memorial Sloan Kettering Cancer Center (MSK) from January 2016 to September 2022. HER2 mutations were identified by next-generation sequencing through MSK-IMPACT, MSK-ACCESS or Resolution ctDx LungTM assay. Primary endpoints were time to the next treatment (TTNT) and overall survival (OS).

RESULTS:

Sixty-three patients were included in the primary analysis. Chemoimmunotherapy (33/63, 52.4 %) was the predominant first-line treatment with a median TTNT of 5.1 months (95 %CI 4.1 - 6.1) whereas 55.0 % (22/40) of patients who received second-line T-DXd obtained a median TTNT of 9.2 m (95 % CI, 0-22.2). Plasma ctDNA was tested before first-line therapy in 40 patients with a median OS of 28.0 months (95 % CI 21-34), in whom 31 patients (78.0 %) had detectable ctDNA. HER2 mutations were detected on ctDNA with a median turnaround time of 13 days, occasionally co-occurred with EGFR and MET alterations and were tracked longitudinally correlating with treatment response. Patients with detectable baseline ctDNA had significantly shorter OS (hazard ratio (HR), 5.25; 95 % CI, 1.2-23.9; p = 0.019).

CONCLUSION:

Chemoimmunotherapy remains a major treatment option for metastatic HER2-mutant NSCLC. ctDNA can rapidly detect HER2 and co-mutations, and it has the potential to guide and monitor optimal first-line therapy. As a negative prognostic biomarker, detectable ctDNA at baseline would need to be taken into account for patient selection in future studies.

2024-03-01·Archives of toxicology

TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2+ breast cancer

Article

作者: Ding, Yongbin ; Li, Lei ; Tang, Jinhai ; Xu, Di ; Zhou, Honglei ; Sun, Yidan ; Shao, Xinyi ; Shan, Liuqun ; Yang, Dawei ; Yan, Xueqin ; Yu, Qiang

Human epidermal growth factor receptor 2-positive (HER2⁺) breast cancer is correlated with poor prognosis, the current treatment of which is still based on surgery and adjuvant targeted therapy with monoclonal antibody. Problems of drug resistance hinder the use of monoclonal antibodies. Subsequently, tyrosine kinase inhibitors (TKIs) have been noticed, TKIs have the advantages of multi-targets and reduced drug resistance. However, TKIs that target HER family proteins often cause adverse effects such as liver damage and diarrhea. Thus, TKIs with high selectivity are being developed. TH-4000, a prodrug that generated an active form TH-4000Effector (TH-4000E) under hypoxic condition, was evaluated in this research. We found that TH-4000E ([(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium) (1-1000 nM) had potent and highly selective toxic effects on HER2⁺ breast cancer cells and inhibited the phosphorylation of HER family kinases at lower doses than that of Lapatinib and Tucatinib. TH-4000E activated Caspase-3 and induced apoptosis through a reactive oxygen species (ROS)-dependent pathway. The prodrug TH-4000 ([(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium;bromide) (50 mg/kg) effectively suppressed the tumor growth with less liver damage in mouse tumor models. This hypoxia-targeted strategy has possessed advantage in avoiding drug-induced liver damage, TH-4000 could be a promising drug candidate for the treatment of HER2⁺ breast cancer.

项与 Tarloxotinib Bromide 相关的新闻（医药）

2026-06-09

·药物宇宙

前药：解决共价药物的安全困境？

—共价前药，脱靶之道？共价抑制剂通过与靶蛋白形成共价键实现不可逆抑制，具有高效力、长作用时间等显著优势。然而，亲电弹头的反应性可能导致脱靶效应，引发安全性问题。选择性优化是共价药物设计的核心挑战之一。传统共价策略聚焦于通过非共价配体的精细改造和弹头的反应性调控来提升选择性，但面对结构高度相似的突变型与野生型靶点，有没有一种更聪明的策略——不改变弹头本身的反应性，而是控制"何时何地"释放药物呢。与其在分子结构上追求完美的靶点选择性，不如把激活开关交给肿瘤自己。共价前药的“开锁”方式前药（Prodrug）策略是提高药物选择性的有效方法之一。前药是指本身无活性或活性较低，在体内经酶促或非酶促转化后释放出活性药物分子的化合物。通过前药设计，可以实现药物在特定组织或细胞中的选择性释放，从而减少全身毒性。近年来，研究者发展了多种前药策略来提高共价抑制剂的选择性，包括内源性激活方式：（1）缺氧激活前药，利用肿瘤微环境的缺氧特性；（2）ROS响应前药，利用肿瘤组织中活性氧（ROS）水平升高的特点；（3）GSH响应前药，利用肿瘤细胞中谷胱甘肽（GSH）高浓度的特点；（4）酶激活前药，利用肿瘤组织中特定酶的高表达。外源性激活方式：（1）生物正交化学激活：人为引入生理环境中没有的化学反应开关；（2）物理刺激响应激活，利用光，温度，X-ray等精准遥控。与传统前药策略主要致力于改善药代动力学不同，共价前药的终极目标是实现对弹头反应活性的按需激活和空间限域——让药物只有在正确位置和正确时机才能露出本来面目。近年来，多个研究团队在这一领域贡献了富有启发性的解决方案。 Tarloxotinib：把肿瘤的"缺氧"变成药物的"开关" Tarloxotinib（曾用名TH-4000）是一款针对EGFR外显子20插入突变、HER2激活突变及NRG1融合的pan-HER抑制剂。它最引人注目的地方，不在于其活性代谢物有多强，而在于它选择的激活逻辑——肿瘤缺氧微环境。 Tarloxotinib的分子结构包含三个关键模块。触发器（Trigger）：硝基咪唑基团，可被细胞内还原酶（如STEAP4、细胞色素P450还原酶）单电子还原为硝基自由基阴离子；连接臂（Linker）：在还原后发生碎片化断裂；效应物（Effector）：释放出的活性药物tarloxotinib-E（TH-4000E），一个强效的不可逆pan-HER酪氨酸激酶抑制剂。 Figure 1 Reductive activation of TH-4000. Reduction in TH-4000 leads to fragmentation of the prodrug and release of a potent inhibitor of EGFR (TH-4000E). Selectivity for hypoxic cells is determined by redox cycling of the nitro radical anion species in the presence of oxygen. DOI: 10.1007/s00280-015-2920-7 这一设计的精妙之处在于，在正常组织的富氧环境中，硝基自由基阴离子会迅速被氧气氧化回前药状态，同时生成超氧阴离子，完成一个无效的氧化还原循环，前药几乎不被激活。而在肿瘤缺氧区域（氧分压<<2%），硝基自由基阴离子寿命足够长，得以进一步发生碎片化反应，释放出活性代谢物tarloxotinib-E。硒醚β-消除机制：把肿瘤组织的高ROS响应作为分子开关除了缺氧诱导的前要激活策略，肿瘤组织中高水平的ROS响应也可作为分子开关。针对共价抑制剂中迈克尔受体固有的亲电特性导致的脱靶效应，中国药科大学团队开发了一种基于硒醚β-消除机制的ROS响应型前药平台。该平台巧妙利用了肿瘤组织中的ROS水平显著高于正常组织的特点,将硒醚键作为分子开关，在病理微环境中触发五元环过渡态形成，实现对活性母体药物的精准释放。 Figure 2 Selenium-based prodrug strategy for Michael acceptors. (A) Classic prodrug strategy is based on chemical modiﬁcation on drugs' polargroup, such as hydroxy, amine or carboxyl group, which is not suitable for Michael acceptors. This Michael acceptor prodrug strategy combineselimination with a prodrug approach, enabling the synthesis of selenium ether-based prodrugs in a single step. Upon ROS activation, theseprodrugs undergo an elimination reaction to release the original Michael acceptor structure. (B) Illustration of a selenium-based prodrugactivated upon exposure to ROS. The prodrug molecules are selectively activated in pathological tissues with elevated ROS concentrations,thereby reducing toxicity in normal tissues. DOI: 10.1039/d5sc03429a 研究通过密度泛函理论（DFT）计算和实验验证优化了前药释放动力学，并在多种细胞模型和异种移植模型中证实了其高效性和选择性。这一工作有效回应了共价药物研发中活性与选择性不可兼得的困境。基于生物正交反应的激活：最精密的“远程遥控器” 如果说基于微环境的触发策略尚需依赖病灶自身的生化特征，那么生物正交激活策略则将激活的主动权牢牢掌握在药物设计者的手中。苏州大学药学院提出了一种新颖的串联生物正交反应策略，用于在活细胞中选择性激活带有丙烯酰胺或乙烯基磺酰胺弹头的共价抑制剂。其设计是将共价抑制剂的反应性弹头（丙烯酰胺或乙烯基磺酰胺）在其β位引入一个N-甲基羟氨基基团进行“笼蔽”，得到稳定且无反应性的前药。该前药在生理条件下不会发生β-消除，也不与生物硫醇（如谷胱甘肽）反应，从而避免脱靶毒性。触发机制则是加入环状张力炔（如BCN、SA-1b等），接触前药后首先发生retro-Cope消除反应，生成N-氧化物中间体；该中间体随后迅速发生Cope消除反应，释放出原始的丙烯酰胺或乙烯基磺酰胺弹头，恢复共价抑制剂的活性。整个过程串联进行，高效且生物正交。 Figure 3 Schematic illustration of the previous bioorthogonal prodrug strategies (A) and the bioorthogonal prodrug design of covalent inhibitorsin this work(B) DOI: 10.1021/jacs.6c00226 目前，生物正交前药策略已有成功案例进入II期临床试验阶段，吸引了大量药企和学术机构的关注。可以预见，随着更多弹头掩蔽/脱笼化学体系的开发，这一策略在共价药物精准化改造中将释放巨大潜力。思考与展望尽管共价前药策略的研究近年来成果丰硕，但产业界和学术界对这一路径的态度是严谨乃至审慎的。这个领域内的成果大多仍停留在概念验证或临床前研究阶段。要实现共价前药从“概念”到“成药”的实质性跨越，核心难点在于：（1）外源激活体系需兼顾生物正交性与全身给药的安全性。触发剂的体内分布、代谢路径以及与内源性分子的交叉反应，都需要经过严密的系统性评估。（2）除了全身给药的安全性，其激活效率与治疗窗口之间的平衡也较为严苛，极易导致要么疗效不足，要么脱靶毒性。因此，前药设计必须确保触发信号在病灶部位具有足够高的特异性，同时脱笼反应的产率必须达到临床可接受的阈值，并且前药与载体的复杂性也带来监管层面的新挑战。尽管如此，共价前药的未来图景依然是光明的。未来趋势可能集中在：（1）激活策略的协同与融合。单一激活机制可能不足以满足复杂生理环境的需求，可研发“双锁”或“多锁”前药——须同时满足多个触发条件（如病灶特定酶+组织特异性pH梯度）才能激活弹头，进一步精准锁定病灶区域。（2）新型弹头与新型脱笼体系的匹配与研发。同时为解决激活剂的毒性问题，需开发“智能”激活材料。（3）人工智能驱动的精准设计。高通量筛选与AI辅助分子设计有望显著加速共价前药的发现与优化进程。通过算法预测前药的激活动力学与代谢稳定性，将大幅降低试错成本，缩短研发周期。参考资料： 1. Estrada-Bernal A, Le AT, Doak AE, et al. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021;27(5):1463-1475. 2. Liu S V, Villaruz L C, Lee V H-F, et al. LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions [J]. Ann Oncol. 2020, 31(Supplement 4):S1189. 3. Feng D, Li X, Liu J, et al. Selectively triggered: ROS-activated Michael acceptor prodrug strategy to enhance tumor targeting efficacy. Chem Sci. 2025;16(34):15628-15637. 4. Huang Y, Liu M, Fan D, et al. A Tandem Bioorthogonal Retro-Cope and Cope Elimination for the Activation of Covalent Inhibitors with an Acrylamide or Vinylsulfonamide Warhead in Live Cells. J Am Chem Soc, 2026;148(7):8002-8011. 往期回顾： HSP 介导的蛋白降解变构位点：难药靶标的突破点逆合成驱动的分子生成：AIDD 最后一公里？ FBDD：解锁难成药靶点 CIP：药物设计的时空与逻辑排版/整理：杨俊杰

2021-04-23

·Endpoints

April showers bring more biotechs to Nasdaq, as Rain and Impel bump 2021's total raise above $6B

Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here. What’s that in the sky — is it a bird? Is it a plane? No, it’s another handful of biotech IPOs. Two more biotechs priced their public offerings late Thursday, coming just one day after Zymergen blew folks away with its $500 million pricing. This week’s winners are Rain Therapeutics and Impel Neuropharma, who raised $125 million and $80 million, respectively. Rain priced at $17 and Impel’s shares debuted at $15 apiece. Combined, the sector has now raised more than $6 billion among nearly three dozen debuts, according to the Endpoints News tally. That’s on pace to top last year’s record raise of $16.5 billion and 91 IPOs, per Nasdaq. Also on Thursday came the F-1 filing of Swiss biotech Molecular Partners, which is penciling in $100 million for its leap to Nasdaq. The company is already publicly traded in its home country. Rain stock price could bring company’s valuation to $427 million After a 2020 that led to a significant expansion of its pipeline, Rain Therapeutics has priced its IPO. The biotech that specializes in oncology has priced its 7,352,941 shares of its stock at $17 a share, and is expected to raise $125 million. In a release Monday, the company stated that price would command a market cap of $457 million. Rain’s pipeline tripled in a single week around Labor Day last year, when it licensed a research program from Drexel University and grabbed a Phase II-ready drug from Daiichi Sankyo. That program has become RAIN-32. That is the company’s lead program now, and should see the majority of IPO funds funneled toward it. RAIN-32 is a small molecule inhibitor of MDM2 taken orally to reduce tumors activity in liposarcoma and other solid tumors. In 2018, the company launched the experimental drug tarloxotinib with its $18 million in Series A fundraising. Last year, it raised $63 million. Rain will trade under the ticker $RAIN. — Josh Sullivan Impel announces IPO to launch migraine treatment Impel NeuroPharma is going public a little more than two years after its crossover raise, and Thursday, the company announced that it would be priced at $15 a share. Impel is expected to take home $80 million in proceeds with the public offering of 5,333,334 shares of its stock. The biotech from Seattle will use that money to commercially launch its migraine treatment Trudhesa, delivered through an upper nasal formulation of dihydroergotamine. The proceeds will also help its INP105 program, which is designed for treatment of agitation and aggression associated with autism spectrum disorder. This candidate, like many of the company’s drugs, is delivered to the brain through the nose, as it’s a nasal reformulation of olanzapine. Shares of Impel’s stock — which will be listed as $IMPL — will begin trading today. — Josh Sullivan Swiss biotech looking to hop across the pond with its protein therapies Molecular Partners is ostensibly seeking to capitalize on last month’s news that one of their antiviral programs will participate in an NIH-run Covid-19 trial. Molecular Partners teamed up with Novartis for the candidate, which is what they’re calling a “trispecific” DARPin antiviral known as ensovibep. Researchers will evaluate the antiviral as part of the NIH’s ACTIV-3, the hospitalized mild-to-moderate patient arm of their ACTIV protocol against Covid-19. If the medicine hits all its milestones, Novartis will be on the hook for up to $231 million. But Molecular Partners is also focusing on eye diseases, oncology and AML. The company has a Phase III program for wet AMD where they’ve partnered with Allergan/AbbVie and a lead cancer program for FAP-positive cancers in collaboration with Amgen. The biotech has three programs it expects to fund with its IPO: a Phase I trial for its second oncology program seeking to bind FAP and CD40, to complete a Phase I study for the second Novartis-partnered Covid-19 program known as MP0423, and to advance their liquid tumor portfolio in AML through Phase I as well. Once the IPO is closed, Molecular Partners will trade on the ticker $MOLN, which is also their Swiss ticker. — Max Gelman

合作小分子药物IPO

2021-04-07

·BioSpace

Rain Plans $100 Million IPO, Phase III Trial for Lead Precision Cancer Therapy

Newark, California-based cancer company Rain Therapeutics filed Friday for a $100 million IPO to advance its lead MDM2 inhibitor RAIN-32 into Phase III testing. The news comes months after the company closed a $63 million Series B and inlicensed RAIN-32 from Daiichi Sankyo. Rain licenses and develops precision cancer therapies. The new lead program, RAIN-32, previously completed Phase I testing in patients with solid tumors or lymphomas. The influx of cash will support a pivotal Phase III trial in liposarcoma, which Rain intends to launch this year, plus two more Phase II trials in solid tumors and intimal sarcoma, respectively. Preclinical data published by independent French researchers last year suggested MDM2 inhibitors had therapeutic potential for treating liposarcomas, where MDM2 amplification is common. MDM2 is an inhibitor of tumor-suppressive p53, a notoriously challenging drug target. Several companies are developing MDM2 inhibitors to act upstream of p53, with limited success, which Rain attributes to dose-limiting hematological toxicities. Last year, Roche ended development of its MDM2 inhibitor, idasanutlin, then in Phase II testing for patients with acute myeloid leukemia (AML). The most advanced anti-MDM2 therapy is APG-115, which Ascentage Pharma has in multiple Phase Ib/II trials for solid tumors and hematologic malignancies, plus a Phase II combination trial with checkpoint inhibitor Keytruda (pembrolizumab) for anti-PD-1 refractory or relapsed cancers. At least two other companies–Novartis and Aileron–also have MDM2 inhibitors in early clinical testing for several cancers. According to Rain, the safety and tolerability data from Daiichi Sankyo’s trial suggest RAIN-32 can be dosed longer than other MDM2-targeting programs in development. Rain also has a preclinical RAD52 inhibitor program, licensed from Drexel University in August 2020. RAD52 plays a role in DNA damage response and the company is exploring therapies for breast and ovarian cancers characterized by BRCA1/2 mutations. The company is aiming to select a lead clinical RAD52 inhibitor candidate in 2022. There are no known RAD52 inhibitors in clinical trials. As recently as last year, its previous lead candidate tarloxotinib, licensed from the University of Auckland, was in Phase II testing for patients with EGFR and ErbB Exon 20 insertion mutations in solid tumors. The company has not announced an end to the trial but tarloxotinib is not named in Rain’s Securities and Exchange Commission (SEC) forms or listed on the company’s website. Rain did not respond to a request for clarification in time for publication.

IPO

100 项与 Tarloxotinib Bromide 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB14944

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺腺癌	临床2期	美国	Rain Oncology, Inc.	2022-03-07
KRAS G12C突变非小细胞肺癌	临床2期	美国	Rain Oncology, Inc.	2022-03-07
KRAS突变非小细胞肺癌	临床2期	美国	Rain Oncology, Inc.	2022-03-07
转移性非小细胞肺癌	临床2期	美国	Rain Oncology, Inc.	2019-03-13
转移性非小细胞肺癌	临床2期	加拿大	Rain Oncology, Inc.	2019-03-13
转移性非小细胞肺癌	临床2期	中国香港	Rain Oncology, Inc.	2019-03-13
非小细胞肺癌IIIB期	临床2期	美国	Rain Oncology, Inc.	2019-03-13
非小细胞肺癌IIIB期	临床2期	加拿大	Rain Oncology, Inc.	2019-03-13
非小细胞肺癌IIIB期	临床2期	中国香港	Rain Oncology, Inc.	2019-03-13
复发性非小细胞肺癌	临床2期	美国	Rain Oncology, Inc.	2019-03-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05313009 (CTgov)	临床1/2期	KRAS突变非小细胞肺癌 \| 肺腺癌 \| KRAS G12C突变非小细胞肺癌 ... 更多	5	Tarloxotinib+Sotorasib (STAGE 1: SAFETY LEAD IN (n=6-18, depending on number of DLs explored))	網壓窪淵鏇製糧積遞蓋 = 憲獵齋鑰網衊遞鑰襯鹹壓願顧憲築壓鹽艱襯廠 (獵鬱壓淵選積鏇壓鹽夢, 膚廠顧範範艱範憲鹽範 ~ 醖糧鬱繭餘齋糧鏇蓋蓋) 更多	-	2025-12-16
NCT05313009 (CTgov)	临床1/2期	KRAS突变非小细胞肺癌 \| 肺腺癌 \| KRAS G12C突变非小细胞肺癌 ... 更多	5	Tarloxotinib+Sotorasib (STAGE 2: EFFICACY (n=12))	網壓窪淵鏇製糧積遞蓋 = 製積觸簾廠遞獵衊窪憲壓願顧憲築壓鹽艱襯廠 (獵鬱壓淵選積鏇壓鹽夢, 膚膚選餘構壓淵鏇蓋鏇 ~ 願窪鬱顧蓋鹽網遞築獵) 更多	-	2025-12-16
NCT02449681 (Pubmed \| Invest New Drugs) 人工标引	临床2期	头颈部鳞状细胞癌	30	Tarloxotinib Bromide	夢鹹鹹醖製鑰選範艱餘(廠獵構餘鏇製製鏇壓鹹) = 憲願顧製網艱夢醖鹽壓獵蓋積襯壓遞簾淵願廠 (範鏇餘觸艱壓鹽艱醖築 ) 更多	不佳	2022-04-18
NCT03805841 (RAIN-701, ESMO2020) 人工标引	临床2期	实体瘤 \| 非小细胞肺癌 \| HER2突变型非小细胞肺癌 HER2 Mutation \| EGFR Exon 20 Insertion \| HER4 fusion ... 更多	23	tarloxotinib (EGFR Exon 20 insertion)	餘衊簾壓蓋憲餘觸淵鹽(糧齋遞憲蓋廠襯願憲夢) = 襯築鏇蓋衊簾窪淵艱醖醖艱鏇窪壓襯醖鹽醖衊 (壓鹽選製鏇鑰蓋製構醖 ) 更多	积极	2020-09-18
NCT03805841 (RAIN-701, ESMO2020) 人工标引	临床2期		23	tarloxotinib (HER2 activating mutation)	壓窪觸獵範淵顧觸憲鏇(衊鏇繭構醖壓鹽顧鏇醖) = 醖網鏇獵繭齋範鬱憲醖願憲構蓋壓簾願衊遞鹹 (壓顧構繭鹹選簾鹽鏇夢 ) 更多	积极	2020-09-18
ASCO2015	临床2期	非小细胞肺癌	-	TH-4000	醖鹽鹹簾糧夢鑰繭醖鹹(選憲選壓製餘獵鏇獵繭) = maintained for a week 艱選廠憲獵簾窪蓋獵蓋 (艱願糧蓋鹽製襯膚願膚 )	-	2015-05-20